#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Intracranial germ cell tumour Short stature homeobox gene mutation Gastroenteropancreatic neuroendocrine tumour disease Wolfram syndrome Leber's congenital amaurosis Small cell lung cancer recurrent Gastrointestinal disorder Neuroendocrine tumour of the lung Thalassaemia beta Synovitis Non-small cell lung cancer recurrent Interstitial lung disease Myelofibrosis Optic glioma High-grade B-cell lymphoma More trials…

    Learn about Rare Diseases

    Brain stem glioma – Treatment Hereditary motor and sensory neuropathy – Life with Disease Osteosarcoma – Diagnostics Basal cell naevus syndrome – Treatment Cholangitis sclerosing Haemolytic uraemic syndrome Angiosarcoma non-metastatic – Diagnostics Pulmonary fibrosis – Basic Information Angelman’s syndrome Breast angiosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Interferon Beta-1A Bjt-778 Caplacizumab N-Acetylhistidine Talquetamab Elraglusib Paroxetine IHMA-2121908-1 Lutetium (177Lu) Oxodotreotide Xylitol Naporafenib Art6043 Lenograstim Pioglitazone Metamizole Magnesium Dazukibart Cyclophosphamide Monohydrate Travoprost Filgotinib Cabazitaxel More therapies…

    Learn about Your Condition

    Synovial sarcoma metastatic Vulval cancer Pyelonephritis Macular telangiectasia Muscle spasticity Skin wrinkling Genitourinary tract neoplasm Hypertonic bladder Gouty arthritis Testicular leiomyosarcoma Metastases to rectum Antisynthetase syndrome Mast cell activation syndrome Deafness Spinal osteoarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    • Epcoritamab
    Czechia Denmark France Germany Hungary The Netherlands +1

  • Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bleomycin
    • Bleomycin Sulfate
    • Brentuximab Vedotin
    Belgium Czechia Denmark France Hungary Italy +3

  • Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Acp-017
    • Pembrolizumab
    • Transcon Il-2Β/Γ
    Germany Hungary Italy Poland Spain

  • Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anakinra
    • Bendamustine Hydrochloride
    • Buclizine Hydrochloride
    Austria Belgium Denmark Finland France Germany +7

  • Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Niraparib Tosilate Monohydrate
    • Pembrolizumab
    Belgium Bulgaria France Germany Greece Hungary +8

  • Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Carboplatin
    • Cisplatin
    Austria Czechia France Germany Hungary Italy +3

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

    Not recruiting

    3 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Ibrutinib
    Austria Belgium Czechia France Greece Hungary +5

  • Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Bemarituzumab
    • Capecitabine
    • Fluorouracil
    Austria Belgium Bulgaria Czechia France Germany +6

  • Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Apalutamide
    Austria Belgium Czechia Denmark Finland Germany +7
Previous Page
1 … 9 10 11 12 13 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!